Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokineticsSBS-147 is a novel and potent oral ...
I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.
A former post-doctoral biology researcher at Indiana University was sentenced after pleading guilty to smuggling biological ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first ...
Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the ...
Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...
As climate change outpaces the ability of ecosystems to adapt, scientists are turning to conservation genomics to guide ...
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Na ...
Marvel Biosciences Corp. (TSXV: MRVL \| OTC: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively ...
IDEAYA Biosciences (IDYA) nears key phase 3 darovasertib data in uveal melanoma, with 3–4 years cash runway and FDA potential ...
Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates from the company’s Partial Epigenetic Reprogramming platform ...
Integrating proteomics with systems biology reveals complex cellular networks, improving disease mechanisms understanding and precision medicine applications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results